MLAB · Mesa Laboratories Inc /Co/ - Financials
Annual line items from SEC XBRL filings, sourced from EDGAR's Company Facts API with fallback to the quarterly Financial Statement Data Sets. See issuer overview for Form 4 activity and 10-K signals.
Income Statement
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $240.98M | $216.19M | $219.08M | $184.34M | $133.94M | $117.69M |
| Cost of Revenue | $90.11M | $82.94M | $85.39M | $75.25M | $46.92M | $52.75M |
| Gross Profit | $150.87M | $133.25M | $133.69M | $109.09M | $87.01M | $64.93M |
| R&D | $19.52M | $19.30M | $20.49M | $15.77M | $10.39M | $6.36M |
| SG&A | $73.33M | $72.87M | $72.44M | $60.31M | $45.70M | $37.83M |
| Total Operating Expenses | $134.53M | $405.32M | $130.37M | $104.39M | $74.66M | $57.44M |
| D&A | $5.38M | $4.23M | $33.82M | $25.07M | $17.66M | $12.99M |
| Operating Income | $16.34M | ($272.07M) | $3.32M | $4.70M | $12.36M | $7.49M |
| Interest Expense | $5.70M | $5.70M | $4.77M | $3.88M | $8.02M | $5.50M |
| Income Tax | $7.93M | ($21.40M) | ($1.32M) | $1.70M | ($971.0K) | $2.08M |
| Net Income | ($1.97M) | ($254.25M) | $1.87M | $1.87M | $3.27M | $1.35M |
| EPS - Basic | ($0.36) | ($47.20) | $0.17 | $0.36 | $0.66 | $0.32 |
| EPS - Diluted | ($0.36) | ($47.20) | $0.17 | $0.35 | $0.64 | $0.31 |
Balance Sheet
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $27.32M | $28.21M | $32.91M | $49.35M | $263.87M | $81.38M |
| Accounts Receivable | $41.97M | $39.05M | $42.55M | $41.22M | $23.79M | $21.13M |
| Inventory | $25.36M | $32.67M | $34.64M | $24.61M | $11.18M | $14.23M |
| Accounts Payable | $5.75M | $6.04M | $6.13M | $7.90M | $4.47M | $3.41M |
| Current Assets | $102.69M | $109.35M | $118.97M | $124.32M | $303.75M | $122.79M |
| Total Assets | $433.35M | $446.80M | $661.83M | $707.37M | $601.48M | $420.21M |
| Current Liabilities | $163.96M | $44.31M | $43.36M | $48.05M | $32.58M | $26.01M |
| Long-term Debt | $71.25M | - | - | - | - | - |
| Total Liabilities | $273.52M | $301.40M | $268.35M | $313.57M | $195.25M | $200.19M |
| Stockholders' Equity | $159.83M | $145.39M | $393.48M | $393.80M | $406.23M | $220.01M |
| Retained Earnings | ($188.94M) | ($183.49M) | $74.20M | $76.67M | $72.46M | $71.93M |
Cash Flow
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | $46.81M | $44.13M | $27.98M | $39.22M | $37.07M | $26.56M |
| Investing Cash Flow | ($4.50M) | ($81.31M) | ($9.49M) | ($305.23M) | ($1.99M) | ($185.59M) |
| Financing Cash Flow | ($44.51M) | $32.84M | ($33.33M) | $52.58M | $146.23M | $231.28M |
| CapEx | $4.25M | $2.57M | $4.54M | $4.43M | $1.99M | $1.50M |
| Free Cash Flow | $42.56M | $41.57M | $23.44M | $34.79M | $35.08M | $25.06M |
Ratios
| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Profitability | ||||||
| Gross margin | 62.6% | 61.6% | 61.0% | 59.2% | 65.0% | 55.2% |
| Operating margin | 6.8% | -125.9% | 1.5% | 2.6% | 9.2% | 6.4% |
| EBITDA margin | 9.0% | -123.9% | 17.0% | 16.1% | 22.4% | 17.4% |
| Net margin | -0.8% | -117.6% | 0.9% | 1.0% | 2.4% | 1.1% |
| Free cash flow margin | 17.7% | 19.2% | 10.7% | 18.9% | 26.2% | 21.3% |
| FCF / Net income | -21.56 | -0.16 | 12.53 | 18.59 | 10.72 | 18.58 |
| R&D / Revenue | 8.1% | 8.9% | 9.4% | 8.6% | 7.8% | 5.4% |
| SG&A / Revenue | 30.4% | 33.7% | 33.1% | 32.7% | 34.1% | 32.1% |
| Effective tax rate | 133.1% | - | -238.9% | 47.6% | -42.2% | 60.7% |
| Return on assets | -0.5% | -56.9% | 0.3% | 0.3% | 0.5% | 0.3% |
| Return on equity | -1.2% | -174.9% | 0.5% | 0.5% | 0.8% | 0.6% |
| Return on invested capital | 3.5% | - | - | - | - | - |
| Liquidity | ||||||
| Current ratio | 0.63 | 2.47 | 2.74 | 2.59 | 9.32 | 4.72 |
| Quick ratio | 0.47 | 1.73 | 1.94 | 2.07 | 8.98 | 4.17 |
| Cash ratio | 0.17 | 0.64 | 0.76 | 1.03 | 8.10 | 3.13 |
| Leverage | ||||||
| Debt / Equity | 0.45 | - | - | - | - | - |
| Debt / Assets | 0.16 | - | - | - | - | - |
| Debt / EBITDA | 3.28 | - | - | - | - | - |
| Interest coverage | 2.9x | -47.8x | 0.7x | 1.2x | 1.5x | 1.4x |
| Equity multiplier | 2.71 | 3.07 | 1.68 | 1.80 | 1.48 | 1.91 |
| Liabilities / Assets | 0.63 | 0.67 | 0.41 | 0.44 | 0.32 | 0.48 |
| Efficiency | ||||||
| Asset turnover | 0.56 | 0.48 | 0.33 | 0.26 | 0.22 | 0.28 |
| Inventory turnover | 3.55 | 2.54 | 2.46 | 3.06 | 4.20 | 3.71 |
| Days sales outstanding | 64d | 66d | 71d | 82d | 65d | 66d |
| Days inventory outstanding | 103d | 144d | 148d | 119d | 87d | 98d |
| Days payable outstanding | 23d | 27d | 26d | 38d | 35d | 24d |
| Cash conversion cycle | 143d | 183d | 193d | 163d | 117d | 140d |
| Valuation | ||||||
| P / E | - | - | 1027.8x | 728.2x | 380.5x | 729.3x |
| P / B | 4.0x | 4.1x | 2.4x | 3.5x | 3.1x | 4.5x |
| P / S | 2.7x | 2.7x | 4.3x | 7.4x | 9.3x | 8.4x |
| EV / EBITDA | 31.6x | - | 24.3x | 44.0x | 32.8x | 44.3x |
| Growth | ||||||
| Revenue growth (YoY) | 11.5% | -1.3% | 18.8% | 37.6% | 13.8% | 14.1% |
| Revenue CAGR (3y) | 9.3% | 17.3% | 23.0% | 21.4% | 16.5% | 7.9% |
| Revenue CAGR (5y) | 15.4% | 16.0% | 20.9% | 14.5% | 9.6% | 10.5% |
| Gross profit growth (YoY) | 13.2% | -0.3% | 22.6% | 25.4% | 34.0% | 6.6% |
| Operating income growth (YoY) | - | - | -29.4% | -62.0% | 64.9% | -23.4% |
| Net income growth (YoY) | 99.2% | - | 0.0% | -42.9% | 142.7% | -82.0% |
| EPS growth (YoY) | 99.2% | - | -51.4% | -45.3% | 106.5% | -83.3% |
| EPS CAGR (3y) | - | - | -18.1% | -42.7% | - | -52.6% |
| EPS CAGR (5y) | - | - | - | -34.5% | -26.4% | -34.8% |
| FCF growth (YoY) | 2.4% | 77.3% | -32.6% | -0.8% | 40.0% | - |
| FCF CAGR (5y) | 11.2% | - | - | - | - | - |
| Book value growth (YoY) | 9.9% | -63.0% | -0.1% | -3.1% | 84.6% | 97.7% |
Sales by segment
From XBRL dimensional facts in the 10-K period ending 2026-03-31.
Business segments
$249.13M totalSterilization And Disinfection Control$101.57M · 40.8%
Calibration Solutions$53.55M · 21.5%
Biopharmaceutical Development$48.63M · 19.5%
Clinical Genomics$45.39M · 18.2%
Product / service
$340.16M totalProduct$203.39M · 59.8%
Consumables$90.52M · 26.6%
Service$45.74M · 13.4%
Hardware And Software$505.0K · 0.1%
Geographic
$249.13M totalUS$116.89M · 46.9%
Other$111.79M · 44.9%
CN$20.45M · 8.2%
Stability scores
Altman Z′
FY 2025 · bankruptcy risk
0.45
Distress
Private-firm variant - uses book equity instead of market cap. > 2.90 safe · 1.23-2.90 grey · < 1.23 distress.
Piotroski F-score
FY 2025 · 9-point quality
6/9
Neutral
- ✗Net income positive
- ✓Operating cash flow positive
- ✓ROA improved YoY
- ✓Cash flow > net income
- -Long-term debt decreased
- ✗Current ratio improved
- ✓No share dilution
- ✓Gross margin improved
- ✓Asset turnover improved
Peer comparison
Same SIC group: Industrial Instruments For Measurement, Display, and Control
Comparing MESA LABORATORIES INC /CO/ against the 5 most active filers in the same SIC group.
Dividends
$0.64/share trailing 12 months · 0.0% YoY
| Ex-date | Per share |
|---|---|
| May 29, 2026 | $0.1600 |
| Feb 27, 2026 | $0.1600 |
| Nov 28, 2025 | $0.1600 |
| Aug 29, 2025 | $0.1600 |
| May 30, 2025 | $0.1600 |
| Feb 28, 2025 | $0.1600 |
| Nov 29, 2024 | $0.1600 |
| Aug 30, 2024 | $0.1600 |
| May 31, 2024 | $0.1600 |
| Feb 28, 2024 | $0.1600 |
| Nov 29, 2023 | $0.1600 |
| Aug 30, 2023 | $0.1600 |
| May 30, 2023 | $0.1600 |
| Feb 27, 2023 | $0.1600 |
| Nov 29, 2022 | $0.1600 |
| Aug 30, 2022 | $0.1600 |
| May 27, 2022 | $0.1600 |
| Feb 25, 2022 | $0.1600 |
| Nov 29, 2021 | $0.1600 |
| Aug 30, 2021 | $0.1600 |
| May 27, 2021 | $0.1600 |
| Feb 25, 2021 | $0.1600 |
| Nov 27, 2020 | $0.1600 |
| Aug 28, 2020 | $0.1600 |